<DOC>
	<DOCNO>NCT01227967</DOCNO>
	<brief_summary>Seasonal influenza responsible many hospitalization death year , despite effective antiviral treatment . Some individual medical condition heart lung disease make particularly risk severe influenza infection may result hospitalization death . Oseltamivir ( Tamiflu ) use often treat flu , still many hospitalization , complication , death even treatment . This study evaluate use combination antiviral ( amantadine , oseltamivir , ribavirin ) compare oseltamivir alone treatment influenza at-risk population .</brief_summary>
	<brief_title>Comparing Efficacy , Safety , Tolerability Combination Antivirals ( Amantadine , Ribavirin , Oseltamivir ) Versus Oseltamivir Treatment Influenza Adults Risk Complications</brief_title>
	<detailed_description>Seasonal influenza responsible approximately 226,000 excess hospitalization annually despite effective antiviral cause significant morbidity mortality ( estimate 24,000-50,000 deaths year United States alone ) . The influenza virus emerge 2009 ( A/California/07/2009 H1N1 ) cause few death ( 12,000 flu-related death U.S ) contrast seasonal flu , nearly 90 percent death 2009 H1N1 occur among people young 65 year age . The CDC define at-risk population responsible majority hospitalization morbidity associate influenza . This study evaluate use combination antiviral compare oseltamivir alone treatment influenza at-risk population . Subjects meet CDC definition at-risk present influenza-like illness screen study . Those subject confirmatory test influenza ( rapid antigen PCR ) randomize 1:1 manner receive blind study treatment consist either combination amantadine , oseltamivir , ribavirin oseltamivir alone 5 day . Clinical , virologic , laboratory assessment Days 1 , 3 , 7 , 14 , 28 use safety efficacy analysis . Objectives : - To evaluate effectiveness combine treatment oseltamivir , amantadine , ribavirin compare oseltamivir alone at-risk individual confirm influenza infection . Eligibility : - Individuals least 18 year age one medical condition may cause complication influenza , develop influenza-like illness . Design : - Participants screen physical examination medical history , along blood test throat swabs confirm influenza infection . - Eligible participant randomly assign take either oseltamivir alone ( current standard treatment influenza ) take oseltamivir , amantadine , ribavirin . Participants additional blood sample throat swabs take start study , show complete study diary home . - Participants receive study medication kit contain medication take home twice day 5 day . - Participants return , medication kit , clinic day 1 ( first day start study ) , 3 , 7 , 14 , 28 . The first visit may take 2 3 hour , subsequent visit take approximately 1 2 hour . Additional blood sample throat swab take visit .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Oseltamivir</mesh_term>
	<mesh_term>Amantadine</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>INCLUSION CRITERIA : Enrollment ( Screening ) 1 . Signed informed consent prior initiation study procedures 2 . Age great equal 18 year age 3 . Presence underlie medical condition ( ) may increase risk complication influenza 4 . History influenzalike illness define : One respiratory symptom ( cough , sore throat , nasal symptom ) AND Either Fever ( subjective document &gt; 38 degree C ) OR 1 constitutional symptom ( headache , malaise , myalgia , sweats/chills fatigue ) 5 . Onset illness 96 hour screen define subject experience least one respiratory symptom , constitutional symptom , fever 6 . Willingness sample store Randomization 1 . Signed informed consent 2 . Age great equal 18 year age 3 . Presence medical condition ( ) associate increase risk complication influenza Age 65 year age old Asthma Neurological neurodevelopmental condition ( include disorder brain , spinal cord , peripheral nerve , muscle cerebral palsy , epilepsy [ seizure disorder ] , stroke , moderate severe developmental delay , muscular dystrophy , spinal cord injury ) [ though still able provide inform consent per inclusion criterion # 1 ] Chronic lung disease ( COPD cystic fibrosis ) Heart disease ( congenital heart disease , congestive heart failure , coronary artery disease ) Blood disorder ( exclude genetic cause anemia , note exclusion criterion ) Endocrine disorder ( diabetes mellitus ) Kidney disorder Liver disorder Metabolic disorder ( inherit metabolic disorder mitochondrial disorder ) Weakened immune system due disease medication ( people HIV/AIDS , cancer , chronic steroid medication cause immune suppression ) BMI â‰¥ 40 4 . Onset illness 96 hour screen define subject experience least one respiratory symptom , constitutional symptom , fever 5 . Positive test influenza ( either rapid antigen PCR ) Results influenza test obtained clinical indication within 12 hour screening/enrollment may use available . Randomization may proceed case discrepant result ( one positive one negative ) 6 . One follow avoid pregnancy : Females able become pregnant ( i.e. , postmenopausal , undergone surgical sterilization , sexually active men ) must agree use least 2 effective form contraception date inform consent 6 month last dose study drug . At least one method contraception barrier method Males undergone surgical sterilization sexually active woman must agree use condom plus partner use least one additional effective form contraception date inform consent 6 month last dose study drug 7 . Willingness sample store EXCLUSION CRITERIA : ( Enrollment Randomization ) 1 . Women pregnant breastfeeding , men whose female partner ( ) pregnant 2 . Inability take oral medication history gastrointestinal malabsorption would preclude use oral medication . 3 . Hemoglobin &lt; 10 g/dL 4 . WBC &lt; 1.5 time 10 ( 9 ) /L 5 . Neutrophils &lt; 0.75 x 10 ( 9 ) /L 6 . Platelets &lt; 50 x 10 ( 9 ) /L 7 . History genetic hemoglobinopathy ( e.g. , thalassemia major sickle cell anemia ) autoimmune hemolytic anemia 8 . Received 2 dos antiviral influenza medication since onset influenza symptom 9 . Received stavudine ( d4T ) , didanosine ( ddI ) , zidovudine ( AZT ) , azathioprine within 30 day prior study entry 10 . Creatinine clearance le 60 mL/min ( estimate CockcroftGault equation use serum creatinine ) 11 . History autoimmune hepatitis 12 . Uncompensated liver disease ( define AST &gt; 3 time site upper limit normal ( ULN ) , ALT &gt; 3 time ULN , Direct Bilirubin &gt; 2 time ULN ) 13 . Clinical sign endstage liver disease include jaundice , coagulopathy , portal hypertension , esophageal varix , ascites , peripheral edema , gastrointestinal bleeding , encephalopathy 14 . Chronic liver disease categorize ChildPugh class C ( ChildPugh score 1015 ) 15 . Known hypersensitivity rimantadine , amantadine , ribavirin , oseltamivir , peramivir , zanamivir 16 . Received live attenuate virus vaccine ( influenza ) within 3 week prior study entry 17 . Use investigational drug within 30 day 5 halflives ( whichever longer ) prior study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Adaptive Design</keyword>
	<keyword>At Risk</keyword>
	<keyword>H1N1</keyword>
	<keyword>Synergy</keyword>
	<keyword>TCAD</keyword>
</DOC>